Transgenomic has appointed Stephen Miller as senior vice president and general manager of its patient testing business unit.
Miller most recently provided commercial and strategic consultancy services to a variety of diagnostic companies, including Transgenomic. Prior to that he was chief commercial officer at BG Medicine. Miller has also served as president and chief commercial officer for Mira Dx, and vice president of sales and marketing at Athena Diagnostics.
NanoString Technologies has appointed David Ghesquiere as senior vice president of corporate and business development.
In this role, Ghesquiere will work with NanoString CEO Brad Gray to shape the company's strategy while leading its corporate and business development efforts, NanoString said.
Ghesquiere joins NanoString most recently from Dendreon, where he served as senior vice president of corporate and business development. He has also served executive roles with OSI Pharmaceuticals (acquired by Astellas) and Aventis Pharmaceuticals (acquired by Sanofi).
NMS Labs has appointed Pierre Cassigneul as president and CEO, and as a member of the board. Cassigneul most recently served as president and CEO of Predictive Biosciences and, prior to that, of XDx.
NMS Labs is an ISO-accredited international forensic and clinical reference laboratory.